STOCK TITAN
  1. Home
  2. Financials
  3. BMGL

Basel Medical Group Ltd Financials

BMGL
Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE June

This page shows Basel Medical Group Ltd (BMGL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BMGL FY2025

Liquidity depends on collecting receivables while new financing rather than operations funded both the cash burn and asset buildout.

The gap between net loss of -$8.4M and operating cash outflow of -$3.2M means reported earnings weakened far faster than cash did, pointing to a large non-cash or balance-sheet component in the loss. Financing inflow of $13.0M then outweighed investing outflow of -$8.6M, showing that outside capital, not internal generation, funded both the year's expansion and its operating shortfall.

The current ratio of 1.3x looks adequate on paper. But accounts receivable at $7.5M far exceed cash of $2.4M, so short-term flexibility depends heavily on collections and customer payment timing rather than on a large cash buffer.

Only capital spending of $438K sat against free cash flow of -$3.6M, so the cash drain was not mainly the cost of maintaining a heavy physical asset base. That makes this a funding structure issue more than a capital intensity issue: the business needed external cash because operations were not covering themselves, and the balance sheet is absorbing that gap.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 19 / 100
Financial Profile 19/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Basel Medical Group Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage
91

Basel Medical Group Ltd carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
21

Basel Medical Group Ltd's current ratio of 1.31 is below the typical benchmark, resulting in a score of 21/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow
0

While Basel Medical Group Ltd generated -$3.2M in operating cash flow, capex of $438K consumed most of it, leaving -$3.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns
0

Basel Medical Group Ltd generates a -195.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Earnings Quality Low Quality
0.38x

For every $1 of reported earnings, Basel Medical Group Ltd generates $0.38 in operating cash flow (-$3.2M OCF vs -$8.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$8.9M

Basel Medical Group Ltd generated $8.9M in revenue in fiscal year 2025.

EBITDA
N/A
Net Income
-$8.4M

Basel Medical Group Ltd reported -$8.4M in net income in fiscal year 2025.

EPS (Diluted)
N/A

Cash & Balance Sheet

Free Cash Flow
-$3.6M

Basel Medical Group Ltd generated -$3.6M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt
$2.4M

Basel Medical Group Ltd held $2.4M in cash against $2.3M in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
19M

Basel Medical Group Ltd had 19M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
-94.0%

Basel Medical Group Ltd's net profit margin was -94.0% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity
-195.6%

Basel Medical Group Ltd's ROE was -195.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
$438K

Basel Medical Group Ltd invested $438K in capex in fiscal year 2025, funding long-term assets and infrastructure.

BMGL Income Statement

Metric Q4'25
Revenue N/A
Cost of Revenue N/A
Gross Profit N/A
R&D Expenses N/A
SG&A Expenses N/A
Operating Income N/A
Interest Expense N/A
Income Tax N/A
Net Income N/A
EPS (Diluted) N/A

BMGL Balance Sheet

Metric Q4'25
Total Assets $14.7M
Current Assets $10.5M
Cash & Equivalents $2.4M
Inventory $385K
Accounts Receivable $7.5M
Goodwill N/A
Total Liabilities $10.4M
Current Liabilities $8.0M
Long-Term Debt $2.3M
Total Equity $4.3M
Retained Earnings -$2.7M

BMGL Cash Flow Statement

Metric Q4'25
Operating Cash Flow N/A
Capital Expenditures N/A
Free Cash Flow N/A
Investing Cash Flow N/A
Financing Cash Flow N/A
Dividends Paid N/A
Share Buybacks N/A

BMGL Financial Ratios

Metric Q4'25
Gross Margin N/A
Operating Margin N/A
Net Margin N/A
Return on Equity N/A
Return on Assets N/A
Current Ratio 1.31
Debt-to-Equity 0.54
FCF Margin N/A

Similar Companies

Cryo-Cell Intl Inc CCEL
$28.6M
Concord Medical CCM
$21.7M
Amer Shared Hosp AMS
$9.6M
Modivcare Inc MODV
$6.2M
NewGenIvf Group NIVF
$2.6M

Frequently Asked Questions

Basel Medical Group Ltd (BMGL) reported $8.9M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Basel Medical Group Ltd (BMGL) reported a net income of -$8.4M in fiscal year 2025, with a net profit margin of -94.0%.

As of fiscal year 2025, Basel Medical Group Ltd (BMGL) had $2.4M in cash and equivalents against $2.3M in long-term debt.

Basel Medical Group Ltd (BMGL) had a net profit margin of -94.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Basel Medical Group Ltd (BMGL) has a return on equity of -195.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Basel Medical Group Ltd (BMGL) generated -$3.6M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Basel Medical Group Ltd (BMGL) generated -$3.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Basel Medical Group Ltd (BMGL) had $14.7M in total assets as of fiscal year 2025, including both current and long-term assets.

Basel Medical Group Ltd (BMGL) invested $438K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Basel Medical Group Ltd (BMGL) had 19M shares outstanding as of fiscal year 2025.

Basel Medical Group Ltd (BMGL) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.

Basel Medical Group Ltd (BMGL) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Basel Medical Group Ltd (BMGL) had a return on assets of -56.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Basel Medical Group Ltd (BMGL) had $2.4M in cash against an annual operating cash burn of $3.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Basel Medical Group Ltd (BMGL) has an earnings quality ratio of 0.38x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Basel Medical Group Ltd (BMGL) scores 19 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top